Becton Dickinson & Co Stock Price, News & Analysis

On September 23, 2020, BD (Becton, Dickinson and Company) submitted a PMA supplement to the FDA for the ThinPrep® Pap Test™ PreservCyt® Solution vial as an approved sample type for its BD Onclarity™ HPV Assay. This submission aims to expand sample claims beyond the BD SurePath™ vial, providing crucial performance data for BD Viper™ LT and BD COR™ Systems. The company recently received FDA approval for extended genotype reporting, enhancing the assay's capabilities. This commitment underscores BD's focus on improving cervical cancer screening and patient management.

BD (Becton, Dickinson and Company) has updated the status of its voluntary recalls of the BD Alaris™ System, initiated on August 4, 2020. The FDA classified three recalls as Class I, indicating a significant risk of serious health consequences or death, while one was classified as Class II. The recalls address issues such as unresponsive keypad keys and incorrect module sizes for infusion pumps, potentially leading to delays or inaccuracies in medication delivery. Customers are advised to follow recall instructions provided by BD.

BD (Becton, Dickinson and Company) announced a study showing the BD Veritor™ System for Rapid Detection of SARS-CoV-2 is as effective as the Quidel Sofia 2 SARS Antigen Fluorescent Immunoassay. The research involved 361 patient samples, indicating a high agreement in testing accuracy. The BD Veritor™ Plus system showed better correlation with PCR results than its competitor. The study aims to assess performance in community settings and highlights the importance of various factors in understanding antigen assay performance. The findings support the rapid antigen tests' utility in managing COVID-19.

BD (Becton, Dickinson and Company) (NYSE:BDX) announced its participation in upcoming virtual investor healthcare conferences. The company will present at the Wells Fargo Securities 2020 Healthcare Conference on September 10, 2020, at 8:40 a.m. EDT, and the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 8:45 a.m. EDT. Webcasts of these presentations will be available on their corporate website and can be replayed for seven days post-conference.

BD (Becton, Dickinson and Company) has updated its voluntary recall of the BD Alaris™ System due to hardware issues. The U.S. FDA has classified three of the situations as Class I recalls, indicating a high probability of serious health risks or death, while one situation is a Class II recall. The issues include damaged connectors and battery problems that may impact device operation. BD has provided corrective instructions to affected customers, emphasizing the importance of safety in medical technology.

BD (Becton, Dickinson and Company) announced the appointment of Kristen Stewart as the senior vice president of Strategy and Investor Relations, effective Aug. 31, 2020. Stewart brings nearly two decades of experience in the medical technology sector, having previously led research at Barclays Capital. Her role will focus on enhancing shareholder value and communicating BD's long-term growth strategy. Tom Polen, CEO of BD, expressed confidence in her strategic skills, while Christopher Reidy, CFO, noted her strong investment community ties.

BD (Becton, Dickinson and Company) will present at the UBS Genomics 2.0 and MedTech Innovations Virtual Summit on August 13, 2020, at 3:30 p.m. ET. A live webcast of the presentation will be available on the BD corporate website and can be replayed until August 20, 2020.

As a leading global medical technology company, BD focuses on improving health care delivery and diagnostics, enhancing safety, efficiency, and access worldwide.

BD (NYSE: BDX) announces a commitment of $7.8 million over three years to support the Helping Build Healthy Communities initiative, enhancing healthcare access for underserved populations. This funding will increase total investments to $22.6 million since 2013. The initiative, in collaboration with Direct Relief and NACHC, focuses on assisting community health centers, which serve nearly 30 million patients. The funds aim to boost innovative healthcare approaches, especially vital during the ongoing COVID-19 pandemic.

BD (Becton, Dickinson and Company) reported Q3 revenue of $3.855 billion, an 11.4% decrease year-over-year. Diluted EPS fell 35.8% to $0.97. Key segments showed mixed results: BD Medical revenue decreased 8.2%, BD Life Sciences dropped 10.1%, while BD Interventional saw a 20.3% decline. Despite challenges, BD noted strong demand for COVID-19 products and positive trends in healthcare procedures. Full-year revenue outlook is a 2.5% to 3.0% decrease, with adjusted EPS guidance between $9.80 and $10.00, reflecting a substantial decline from last year's figures.